RxDoctor Payments Data

Christopher Colburn

Optometrist · Jamestown, NYNPI 1649269861

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 92.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $72 and has fallen 79.7% since, to $15 in 2025. That places this record below the midpoint for optometrist clinicians in NY, where the typical reported total is $538.

$186in general payments, 2019–2025

Across 11 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$172
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$14
$308,188in research payments, 2019–2025

Across 40 payments — averaging $7704.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson Vision Care, Inc.$153K
  • Bausch & Lomb Americas Inc.$88K
  • Bausch Health US, LLC$65K
  • Alcon Research LLC$3K

What the payments were for

  • Food & beverage$186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$186 in reported general payments places this provider in the 25th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$56,608
Medicare patients
364
Services billed
3,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Brimonidine Tartrate16$2,231
Latanoprost124$1,577
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$505
Prednisolone Acetate19$495

Paid to pharmacies, not to this prescriber.

Other optometrist in Jamestown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →